Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

CRISPR Therapeutics

Main focus: Gene editing for the treatment of genetic diseases and cancer

Company stage: Clinical

Diseases: Sickle cell disease, beta-thalassemia, multiple myeloma, haematological malignancies, solid tumours, Type 1 diabetes mellitus, Glycogen storage disease type 1a (GSD 1a), duchenne muscular dystrophy, myotonic dystrophy type 1, cystic fibrosis

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:CRSP)

Location: Zug, Switzerland and Cambridge, MA, USA

Website: http://www.crisprtx.com/

Pipeline: http://www.crisprtx.com/programs/pipeline

Partners: Vertex Pharmaceuticals, ViaCyte, Nkarta Therapeutics, Capsida Biotherapeutics, CureVac, KSQ Therapeutics, Anagenesis Biotechnologies, ProBiogen

CRISPR Therapeutics is a clinical-stage genome-editing company primarily working with haemoglobinopathies, immunooncology, regenerative medicine and other rare diseases. The company has a clinical-stage programme, CTX001 in sickle cell disease and beta-thalassemia, with promising preliminary results so far. Furthermore, the company is investigating three distinct CRISPR-Cas9-modified CAR-T cell therapies. The company is co-founded by Dr. Emanuelle Charpentier and holds multiple important patents within the gene-editing space.

Tags

HashtagCRISPR Therapeutics AG

The CMN Collection of Delivery Articles
Company: CRISPR Therapeutics
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine